News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Unit Held Liable in Australian Vioxx Case
March 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co's (MRK.N) one-time blockbuster arthritis drug Vioxx doubled the risk of heart attacks and was not fit for sale, an Australian court said on Friday, in a ruling against the U.S. group's Australian unit.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Asia
Australia
Merck & Co.
MORE ON THIS TOPIC
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
May 7, 2026
·
2 min read
·
Tristan Manalac
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
April 28, 2026
·
3 min read
·
Tristan Manalac
Drug pricing
Regeneron finally joins Trump’s drug pricing push while notching landmark approval
April 24, 2026
·
2 min read
·
Tristan Manalac